GlobeNewswire Inc.··Pomerantz LlpMereo BioPharma Stock Collapsed 87.7% After Trial Failure; Class Action Deadline Looms
Pomerantz Law Firm filed class action against $MREO after Phase 3 trial failures. Stock plummeted 87.7%. Investor deadline: April 6, 2026.
NAVNSNOWMREOsecurities fraudclass action lawsuit